# US 2025/0085295 A1 · Methods for measuring interactions between proteins comprising an fc portion and particles > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2025/0085295 A1 - Document ID: US20250085295A1 - Status: Published application - Kind: A1 - Application number: 18/883,082 - Filed: 2024-09-12 - Published: 2025-03-13 - Earliest claimed: 2023-09-12 - Assignees: Nanotemper Technologies GmbH - Applicants: Nanotemper Technologies GmbH - Inventors: CHRISTOPHER HEIM; WERNER STREICHER; PHILIPP BAASKE; PHILIPP SCHRAMM - Web page: https://patentgrep.com/patent/US20250085295A1 ## CPC - G01N 33/542: with steric inhibition or signal modification, e.g. fluorescent quenching - G01N 33/6857: {Antibody fragments} - C07K 5/1019: {with the first amino acid being basic} - G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites} - G01N 33/582: {with fluorescent label} - G01N 33/6854: {Immunoglobulins} - C07K 7/06: having 5 to 11 amino acids - C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract The present invention relates to means and methods for measuring an interaction between a fluorescently labelled protein comprising an Fc portion and particles in a solution, wherein said protein comprising an Fc portion is fluorescently labelled by a Fc-binding peptide comprising a fluorescent label. Means may, e.g. be kits or systems which may also be used measuring an interaction between a fluorescently labelled protein comprising an Fc portion and particles in a solution. ## Claims ### Claim 1 A method for measuring an interaction between a fluorescently labelled protein comprising an Fc portion and one or more particles in a solution, comprising analysing alterations in the fluorescence spectrum of said labelled protein comprising an Fc portion upon a potential interaction with said particles, wherein said protein comprising an Fc portion is fluorescently labelled by a Fc-binding peptide capable of binding to said protein comprising an Fc portion within its Fc region, said Fc-binding peptide comprising a fluorescent label, wherein the alterations in the fluorescence spectrum of said labelled protein comprising an Fc portion are analysed by microscale thermophoresis, temperature-related intensity change or spectral shift technology. ### Claim 2 (depends on 1) The method of claim 1, wherein alterations in the fluorescence spectrum are alterations in the fluorescence emission spectrum. ### Claim 3 (depends on 1) The method of claim 1, wherein an alteration in the fluorescence spectrum of said labelled protein comprising an Fc portion is indicative of an interaction between said labelled protein comprising an Fc portion and said particles. ### Claim 4 (depends on 1) The method of claim 1, wherein said particles are selected from the group consisting of organic molecules, biomolecules, nanoparticles, microparticles, vesicles, biological cells or sub-cellular fragments, biological tissues, viral particles, viruses, cellular organelles, lipid nanoparticles (LNPs), and virus like particles. ### Claim 5 (depends on 1) The method of claim 1, wherein said Fc-binding peptide is non-covalently bound to said protein comprising an Fc portion. ### Claim 6 (depends on 1) The method of claim 1, wherein said Fc-binding peptide has an affinity to said protein comprising an Fc portion of at least about 1×10−7 M. ### Claim 7 (depends on 1) The method of claim 1, wherein said Fc-binding peptide comprises 4 to 30 amino acids. ### Claim 8 (depends on 1) The method of claim 1, wherein said protein comprising an Fc portion is an antibody. ### Claim 9 (depends on 1) The method of claim 1, wherein said Fc-binding peptide is (a) (SEQ ID NO: 1) DCAWHLGELVWCT, (b) (SEQ ID NO: 2) L-Pro DCAWHLGELVWCT D-Pro, (c) (SEQ ID NO: 3) CDCAWHLGELVWCTC, (d) (SEQ ID NO: 4) RRGW, (e) (SEQ ID NO: 5) KHRFNKD, (f) (SEQ ID NO: 6) HMVCLAYRGRPVCFAL, (g) (SEQ ID NO: 7) HMVCLSYRGRPVCFSL, or (h) (SEQ ID NO: 8) HQVCLSYRGRPVCFST. ### Claim 10 (depends on 1) The method of claim 1, wherein the fluorescent label is a fluorescent dye. ### Claim 11 (depends on 1) Use of a kit for performing the method of claim 1, comprising (i) a fluorescent label ready to be coupled to a Fc-binding peptide and (ii) a Fc-binding peptide. ### Claim 12 (depends on 1) A kit for use in the method of claim 1, comprising (i) a fluorescent label ready to be coupled to a Fc-binding peptide and (ii) a Fc-binding peptide. ### Claim 13 (depends on 11) The use of a kit according to claim 11, wherein said fluorescence label is already coupled to said Fc-binding peptide. ### Claim 14 A system comprising a Fc-binding peptide comprising (i) a fluorescent label, (ii) a protein comprising an Fc portion which is to be bound by said Fc-binding peptide and (iii) a device configured to analyse alterations in the fluorescence spectrum of said labelled protein comprising an Fc portion upon a potential interaction of said labelled protein comprising an Fc portion with particles, wherein said device is configured to perform microscale thermophoresis, temperature-related intensity change or spectral shift measurement. ### Claim 15 (depends on 14) Use of the system of claim 14 for measuring an interaction between a fluorescently labelled protein comprising an Fc portion and particles in a solution.